Navigation mit Access Keys

  • Search

Search

Forschende im Gespräch

Forschende im Gespräch Unterhaltsam und persönlich – Wissenschaftlerinnen und Wissenschaftler geben kurze und leicht verständliche Einführungen in Forschungsthemen und beantworten Ihre Fragen. Dauer 15 Minuten. Hörsaal, 1.…

Leuchtturm der Wissenschaft

Leuchtturm der Wissenschaft Architekt und Biozentrum geben Einblick in die Entstehung des hochmodernen, zukunftsweisenden Biozentrum Neubaus. Dauer 30 Minuten. 11: 15 und 16:15 Warum verlangt die Spitzenforschung nach einer…

Günther Gerisch

Prof. Dr. Günther Gerisch 1975 – 1979 | Guest Professor for Cell Biology Günther Gerisch studied biology at the “Freie Universität” in West Berlin and the Universities of Göttingen and Tübingen and subsequently earned his…

Overview

SEAL Therapeutics AG: Gene therapy for muscular dystrophy The Biozentrum spin-off develops an innovative gene therapy to treat congenital muscular dystrophy. Cross-section through treated LAMA2 MD muscle with individual…

LAMA2 MD

LAMA2-related muscular dystrophy (LAMA2 MD; also called MDC1A) Congenital muscular dystrophies (CMDs) are a group of genetic muscle diseases with onset at birth or very early infancy. The more than 30 known forms of these…

SEAL Technology

SEAL Technology The innovative gene therapy approach (called SEAL technology), developed by Prof. Markus Rüegg and Prof. Peter Yurchenco and their teams over the past 20 years, overcomes the lack of laminin-α2 in muscle…

Collaborations

International collaborations Founding scientists of SEAL Therapeutics (Prof. Markus A. Rüegg and Dr. Judith Reinhard) have a long-standing collaboration with Prof. Peter Yurchenco and colleagues at Rutgers, the State…

Literature

Literature McKee KK, Yurchenco PD. Amelioration of muscle and nerve pathology of Lama2-related dystrophy by AAV9-laminin-alphaLN linker protein. JCI Insight. 2022;7(13) .

CV

CV of Prof. Dr. Richard Neher ORCID 0000-0003-2525-1407 Google Scholar Google Scholar Nationality: German Positions: Since 2017 Associate Professor, Biozentrum, University of Basel, Switzerland 2010 - 2017 Independent Max…

Contact

SEAL Therapeutics AG c/o Markus A. Rüegg, CEO Biozentrum, University of Basel Spitalstrasse 41 CH-4056 Basel/Switzerland markus-a.ruegg unibas ch http://www.sealtherapeutics.com/ X: @SEAL_Tx Linkedin: Seal-Therapeutics-AG …